Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MESO
MESO logo

MESO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mesoblast Ltd (MESO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
15.200
1 Day change
1.47%
52 Week Range
21.500
Analysis Updated At
2026/05/22
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

MESO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 ready to invest. The stock does not have a strong technical entry, there is no fresh news catalyst, and proprietary trading signals show no buy setup today. If the user is unwilling to wait for a better setup, this is still not an attractive immediate purchase.

Technical Analysis

The technical picture is weak to neutral. MACD histogram is -0.047 and still below zero, though it is only slightly negative and contracting. RSI_6 at 54.74 is neutral, showing no strong momentum either way. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which points to a broader downtrend or weak trend structure. Price at 15.21 is just above pivot 14.776 and below resistance R1 at 15.162 is being tested in pre-market, but the overall setup is not a clean bullish breakout. Support sits at 14.39 and 14.152, while upside resistance is 15.4. The near-term stock trend data also implies mild downside over the next week and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish on the surface because put-call ratios are extremely low. Open interest put-call ratio of 0.13 and option volume put-call ratio of 0.0 indicate heavy call bias and very limited put activity. Call open interest of 27,749 versus put open interest of 3,689 also supports bullish sentiment. However, implied volatility is elevated at 124.96, above historical volatility of 39.66, suggesting the market is pricing in large expected movement and the options market is rich. Overall, sentiment is bullish, but the stock price action is not yet confirming a strong directional move.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
7

Positive Catalysts

  • ["Strongly bullish options positioning with very low put-call ratios", "Pre-market price is above the prior pivot, which could attract momentum buyers if it holds", "No recent negative news reported in the last week"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst", "Technicals remain bearish overall with SMA_200 > SMA_20 > SMA_5", "MACD is below zero and still negative", "Comparable pattern analysis suggests small negative returns over the next week and month", "No AI Stock Picker or SwingMax buy signal today", "No meaningful insider, hedge fund, congress, or influential figure buying activity reported"]

Financial Performance

Latest quarter financial data was not available because the financial snapshot returned an error, so there is no reliable recent-quarter growth assessment to support a buy decision. The latest season cannot be confirmed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. There is therefore no visible recent Wall Street upgrade or target increase trend to support a bullish case. Based on the available information, pros are limited to bullish options sentiment, while the cons are weak technicals, no recent catalyst, and no supportive analyst momentum.

Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
Wall Street analysts forecast MESO stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.980
sliders
Low
35
Averages
35
High
35
Current: 14.980
sliders
Low
35
Averages
35
High
35
Jefferies
Hold
to
Buy
upgrade
$3
AI Analysis
2025-11-25
Reason
Jefferies
Price Target
$3
AI Analysis
2025-11-25
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.
Jefferies
David Stanton
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
David Stanton
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MESO
Unlock Now

People Also Watch